[go: up one dir, main page]

RU2407796C2 - FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION - Google Patents

FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION Download PDF

Info

Publication number
RU2407796C2
RU2407796C2 RU2005123986/13A RU2005123986A RU2407796C2 RU 2407796 C2 RU2407796 C2 RU 2407796C2 RU 2005123986/13 A RU2005123986/13 A RU 2005123986/13A RU 2005123986 A RU2005123986 A RU 2005123986A RU 2407796 C2 RU2407796 C2 RU 2407796C2
Authority
RU
Russia
Prior art keywords
polypeptide
host cell
nucleic acid
region
beta
Prior art date
Application number
RU2005123986/13A
Other languages
Russian (ru)
Other versions
RU2005123986A (en
Inventor
Пабло УМАНА (CH)
Пабло Умана
Петер БРУЭНКЕР (CH)
Петер БРУЭНКЕР
Клаудиа ФЕРРАРА (CH)
Клаудиа Феррара
Тобиас СЬЮТЕР (CH)
Тобиас СЬЮТЕР
Original Assignee
Гликарт Биотекнолоджи АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гликарт Биотекнолоджи АГ filed Critical Гликарт Биотекнолоджи АГ
Publication of RU2005123986A publication Critical patent/RU2005123986A/en
Application granted granted Critical
Publication of RU2407796C2 publication Critical patent/RU2407796C2/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

FIELD: medicine.
SUBSTANCE: invention concerns nucleic acid molecules including the glycolising fusion designs containing catalytic domain of beta-1,4-N-acetylglucosaminyl transferase III or beta-1,4-galactosyl transferase, and resident polypeptide domain of Golgi complex responsible for localisation in Golgi complex, as well as their applications in host cell glycolisation modification.
EFFECT: invention allows producing polypeptides with the improved therapeutic properties, including antibodies with higher Fc-receptor binding and enhanced effector function.
21 cl, 37 dwg, 2 tbl, 7 ex

Description

Текст описания приведен в факсимильном виде.

Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
The text of the description is given in facsimile form.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149

Claims (21)

1. Клетка-хозяин млекопитающего для продуцирования полипептида слияния, обладающего гликозилирующей активностью, причем указанная клетка-хозяин генетически модифицирована для экспрессии по меньшей мере одной нуклеиновой кислоты, кодирующей полипептид слияния, содержащий каталитический домен бета-1,4-N-ацетилглюкозаминилтрансферазы III или бета-1,4-галактозилтрансферазы и отвечающий за локализацию в комплексе Гольджи домен полипептида-резидента комплекса Гольджи.1. A mammalian host cell to produce a fusion polypeptide having glycosylating activity, wherein said host cell is genetically modified to express at least one nucleic acid encoding a fusion polypeptide containing a catalytic domain of beta-1,4-N-acetylglucosaminyl transferase III or beta -1,4-galactosyltransferase and responsible for localization in the Golgi complex is the domain of the Golgi complex resident polypeptide. 2. Клетка-хозяин по п.1, отличающаяся тем, что указанная клетка-хозяин экспрессирует по меньшей мере одну нуклеиновую кислоту, кодирующую полипептид, содержащий Fc-область, и по меньшей мере одну нуклеиновую кислоту, кодирующую полипептид слияния, содержащий каталитический домен бета-1,4-N-ацетилглюкозаминилтрансферазы III или бета-1,4-галактозилтрансферазы, в количестве, достаточном для модификации олигосахаридов в Fc-области указанного полипептида, содержащего Fc-область, продуцируемого указанной клеткой-хозяином.2. A host cell according to claim 1, characterized in that said host cell expresses at least one nucleic acid encoding a polypeptide containing an Fc region, and at least one nucleic acid encoding a fusion polypeptide containing a beta catalytic domain -1,4-N-acetylglucosaminyl transferase III or beta-1,4-galactosyl transferase, in an amount sufficient to modify the oligosaccharides in the Fc region of the polypeptide containing the Fc region produced by the specified host cell. 3. Способ продуцирования полипептида, содержащего Fc-область, с повышенной эффекторной функцией в клетке-хозяине по п.2, включающий:
а. культивирование клетки-хозяина по п.2 в условиях, которые допускают продукцию полипептида, содержащего Fc-область, причем указанный полипептид слияния экспрессируется в количестве, достаточном для модификации олигосахаридов в Fc-области указанного полипептида, содержащего Fc-область, продуцируемого клеткой-хозяином; и
b. выделение указанного полипептида, содержащего Fc-область.3. A method of producing a polypeptide containing an Fc region with increased effector function in a host cell according to claim 2, including:
but. culturing the host cell according to claim 2 under conditions that allow the production of a polypeptide containing the Fc region, said fusion polypeptide being expressed in an amount sufficient to modify oligosaccharides in the Fc region of the polypeptide containing the Fc region produced by the host cell; and
b. the selection of the specified polypeptide containing the Fc region. 4. Полипептид, содержащий Fc-область, продуцируемый по способу согласно п.3, отличающийся тем, что указанный полипептид представляет собой антитело, обладающее повышенной эффекторной функцией по сравнению с немодифицированным антителом.4. A polypeptide containing an Fc region produced by the method according to claim 3, characterized in that said polypeptide is an antibody having enhanced effector function compared to an unmodified antibody. 5. Полипептид, содержащий Fc-область, продуцируемый по способу согласно п.3, отличающийся тем, что указанный полипептид представляет собой фрагмент антитела, обладающий повышенной эффекторной функцией или аффинностью связывания Fc-рецептора по сравнению с немодифицированным фрагментом антитела.5. A polypeptide containing an Fc region produced by the method according to claim 3, characterized in that said polypeptide is an antibody fragment having an increased effector function or binding affinity of the Fc receptor compared to an unmodified antibody fragment. 6. Фармацевтическая композиция для лечения рака, содержащая эффективное количество полипептида, содержащего Fc-область, продуцируемый по способу согласно п.3, и фармацевтически приемлемый носитель.6. A pharmaceutical composition for treating cancer, comprising an effective amount of a polypeptide comprising an Fc region produced by the method of claim 3, and a pharmaceutically acceptable carrier. 7. Способ лечения рака, включающий введение фармацевтического состава по п.6 нуждающемуся в этом пациенту.7. A method of treating cancer, comprising administering a pharmaceutical composition according to claim 6 to a patient in need thereof. 8. Способ лечения заболеваний или нарушений, для лечения которых полезно уменьшение количества В-клеток, включающий введение терапевтически эффективного количества полипептида, продуцируемого по способу согласно п.3, причем указанный полипептид представляет собой антитело.8. A method of treating diseases or disorders for the treatment of which a decrease in the number of B cells is advantageous, comprising administering a therapeutically effective amount of a polypeptide produced by the method according to claim 3, wherein said polypeptide is an antibody. 9. Способ продуцирования полипептида слияния, содержащего каталитический домен бета-1,4-N-ацетилглюкозаминилтрансферазы III или бета-1,4-галактозилтрансферазы, и отвечающий за локализацию в комплексе Гольджи домен полипептида-резидента комплекса Гольджи, включающий культивирование клетки-хозяина по п.1 в среде, в условиях, допускающих экспрессию нуклеиновой кислоты, кодирующей указанный полипептид слияния, и выделение указанного полипептида слияния из полученной в результате культуры.9. A method of producing a fusion polypeptide containing the catalytic domain of beta-1,4-N-acetylglucosaminyl transferase III or beta-1,4-galactosyl transferase, and responsible for the localization in the Golgi complex of the Golgi complex polypeptide-resident domain, comprising culturing the host cell according to claim .1 in an environment under conditions allowing expression of a nucleic acid encoding the specified fusion polypeptide, and isolation of the specified fusion polypeptide from the resulting culture. 10. Полипептид слияния, полученный способом по п.9, содержащий каталитический домен бета-1,4-N-ацетилглюкозаминилтрансферазы III или бета-1,4-галактозилтрансферазы и содержащий отвечающий за локализацию в комплексе Гольджи домен полипептида млекопитающего-резидента комплекса Гольджи.10. The fusion polypeptide obtained by the method according to claim 9, containing the catalytic domain of beta-1,4-N-acetylglucosaminyl transferase III or beta-1,4-galactosyl transferase and containing the domain of the Golgi complex mammalian resident polypeptide in the Golgi complex. 11. Изолированная нуклеиновая кислота, содержащая последовательность, кодирующую полипептид слияния по п.10, причем нуклеиновая кислота имеет последовательность, выбранную из группы, состоящей из: SEQ ID NO:12, SEQ ID NO:14 и SEQ ID NO:19.11. An isolated nucleic acid containing the sequence encoding the fusion polypeptide of claim 10, wherein the nucleic acid has a sequence selected from the group consisting of: SEQ ID NO: 12, SEQ ID NO: 14 and SEQ ID NO: 19. 12. Вектор экспрессии, который содержит изолированную нуклеиновую кислоту по п.11.12. An expression vector that contains an isolated nucleic acid according to claim 11. 13. Способ изменения профиля гликозилирования полипептида, продуцируемого клеткой-хозяином млекопитающего, включающий введение в указанную клетку-хозяина нуклеиновой кислоты по п.11 или включающий введение в указанную клетку-хозяина вектора экспрессии по п.12.13. A method for changing the glycosylation profile of a polypeptide produced by a mammalian host cell, comprising introducing into the specified host cell a nucleic acid according to claim 11 or comprising introducing into the specified host cell the expression vector of claim 12. 14. Полипептид слияния по п.10, обладающий активностью бета-1,4-галактозилтрансферазы.14. The fusion polypeptide of claim 10, having beta-1,4-galactosyltransferase activity. 15. Клетка-хозяин, содержащая вектор экспрессии по п.12.15. A host cell containing the expression vector according to item 12. 16. Клетка-хозяин по п.1, содержащая:
(а) вектор экспрессии, содержащий молекулу нуклеиновой кислоты, кодирующую полипептид слияния, где указанный полипептид слияния содержит каталитический домен бета-1,4-N-ацетилглюкозаминилтрансферазы III(GnTIII) и отвечающий за локализацию в комплексе Гольджи домен полипептида-резидента комплекса Гольджи, и дополнительно (b) вектор экспрессии, содержащий молекулу нуклеиновой кислоты, кодирующую полипептид, содержащий каталитический домен маннозидазы II (ManII).16. A host cell according to claim 1, containing:
(a) an expression vector containing a nucleic acid molecule encoding a fusion polypeptide, wherein said fusion polypeptide contains a beta-1,4-N-acetylglucosaminyl transferase III (GnTIII) catalytic domain and is responsible for the localization of the Golgi complex resident polypeptide domain in the Golgi complex, and additionally (b) an expression vector containing a nucleic acid molecule encoding a polypeptide containing the catalytic domain of mannosidase II (ManII). 17. Клетка-хозяин по п.2, модифицированная для экспрессии по меньшей мере одной нуклеиновой кислоты, кодирующей белок слияния, содержащий каталитический домен GnTIII, и дополнительно по меньшей мере одной молекулы нуклеиновой кислоты, кодирующей полипептид, содержащий каталитический домен Man II, в количестве, достаточном для модификации олигосахаридов в Fc-области полипептида, содержащего Fc-область, продуцируемого указанной клеткой-хозяином.17. The host cell according to claim 2, modified to express at least one nucleic acid encoding a fusion protein containing a GnTIII catalytic domain, and additionally at least one nucleic acid molecule encoding a polypeptide containing a Man II catalytic domain, in an amount sufficient to modify the oligosaccharides in the Fc region of the polypeptide containing the Fc region produced by said host cell. 18. Клетка-хозяин по п.17, модифицированная дополнительно для экспрессии по меньшей мере одной молекулы нуклеиновой кислоты, кодирующей полипептид, содержащий каталитический домен GnTII, в количестве, достаточном для модификации олигосахаридов в Fc-области полипептида, содержащего Fc-область, продуцируемого указанной клеткой-хозяином.18. The host cell according to 17, further modified to express at least one nucleic acid molecule encoding a polypeptide containing a GnTII catalytic domain, in an amount sufficient to modify oligosaccharides in the Fc region of the polypeptide containing the Fc region produced by said host cell. 19. Клетка-хозяин по п.1, содержащая:
(a) вектор экспрессии, содержащий молекулу нуклеиновой кислоты, кодирующую полипептид слияния, где указанный полипептид слияния содержит каталитический домен бета-1,4-N-галактозилтрансферазы (GalT) и отвечающий за локализацию в комплексе Гольджи домен полипептида-резидента комплекса Гольджи, и
(b) вектор экспрессии, содержащий молекулу нуклеиновой кислоты, кодирующую полипептид, содержащий каталитический домен маннозидазы II (ManII).19. The host cell according to claim 1, containing:
(a) an expression vector containing a nucleic acid molecule encoding a fusion polypeptide, wherein said fusion polypeptide contains a beta-1,4-N-galactosyltransferase (GalT) catalytic domain and is responsible for the localization in the Golgi complex of the Golgi complex resident polypeptide domain, and
(b) an expression vector containing a nucleic acid molecule encoding a polypeptide containing the catalytic domain of mannosidase II (ManII). 20. Клетка-хозяин по п.2, модифицированная для экспрессии по меньшей мере одной нуклеиновой кислоты, кодирующей полипептид слияния, содержащий каталитический домен GalT, и дополнительно по меньшей мере одной нуклеиновой кислоты, кодирующей полипептид, содержащий каталитический домен ManII, в количестве, достаточном для модификации олигосахаридов в Fc-области полипептида, содержащего Fc-область, продуцируемого указанной клеткой-хозяином.20. The host cell according to claim 2, modified to express at least one nucleic acid encoding a fusion polypeptide containing a GalT catalytic domain, and additionally at least one nucleic acid encoding a polypeptide containing a ManII catalytic domain, in an amount sufficient for modifying oligosaccharides in the Fc region of a polypeptide containing the Fc region produced by said host cell. 21. Клетка-хозяин по любому из пп.18-20, отличающаяся тем, что указанный полипептид, содержащий Fc-область, продуцируемый указанной клеткой-хозяином, выбирают из группы, состоящей из целой молекулы антитела, и фрагмента антитела. 21. A host cell according to any one of claims 18 to 20, characterized in that said polypeptide containing the Fc region produced by said host cell is selected from the group consisting of an entire antibody molecule and an antibody fragment.
RU2005123986/13A 2003-01-22 2004-01-22 FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION RU2407796C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44130703P 2003-01-22 2003-01-22
US60/441,307 2003-01-22
US49125403P 2003-07-31 2003-07-31
US60/491,254 2003-07-31
US60/495,142 2003-08-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2010135975A Division RU2623167C2 (en) 2003-01-22 2010-08-26 Fusion constructs and their application to create antibodies with high fc receptor binding affinity and with effector function

Publications (2)

Publication Number Publication Date
RU2005123986A RU2005123986A (en) 2007-02-27
RU2407796C2 true RU2407796C2 (en) 2010-12-27

Family

ID=37990181

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2005123986/13A RU2407796C2 (en) 2003-01-22 2004-01-22 FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION
RU2010135975A RU2623167C2 (en) 2003-01-22 2010-08-26 Fusion constructs and their application to create antibodies with high fc receptor binding affinity and with effector function

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2010135975A RU2623167C2 (en) 2003-01-22 2010-08-26 Fusion constructs and their application to create antibodies with high fc receptor binding affinity and with effector function

Country Status (1)

Country Link
RU (2) RU2407796C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104379162B (en) * 2012-03-15 2017-03-15 奥克西雷恩英国有限公司 Methods and materials for treating Pompe's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012340A1 (en) * 1990-02-14 1991-08-22 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules
US5874271A (en) * 1992-08-21 1999-02-23 Takara Shuzo Co., Ltd. Human glycosyltransferase gene, compounds and method for inhibiting cancerous metastasis
RU2133624C1 (en) * 1997-07-25 1999-07-27 Свадовский Александр Игоревич Method for treating intracerebral tumor of the brain
JP2000245464A (en) * 1999-02-25 2000-09-12 Kyowa Hakko Kogyo Co Ltd Novel polypeptide
KR100787073B1 (en) * 2000-06-28 2007-12-21 글리코파이, 인크. Method for preparing modified glycoprotein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SBURLATI A.R. et. al, Synthesis of bisected glycoforms of recombinant IFN-beta by overexpression of beta-1,4-N-acetylglucosaminyltransferase III in Chinese hamster ovary cells. Biotechnol Prog. 1998 Mar-Apr; 14(2): 189-92. *

Also Published As

Publication number Publication date
RU2005123986A (en) 2007-02-27
RU2623167C2 (en) 2017-06-22
RU2010135975A (en) 2012-03-10

Similar Documents

Publication Publication Date Title
CA2064689C (en) Stabilized protein or peptide conjugates
EP0327378B1 (en) Domain-modified constant region antibodies
CN104804093A (en) Single-domain antibody for CD47
NZ603037A (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
JP2023015347A (en) Production of seleno-biologics in genomically recoded organisms
CN1047402C (en) DNA sequences encoding gelonin polypeptide
JP5893597B2 (en) Process for producing glycoproteins characterized by sugar chain structure using silkworms
EP2992021A2 (en) Novel cloning, expression & purification method for the preparation of ranibizumab
EP3966238A2 (en) Variant domains for multimerizing proteins and separation thereof
US20050207977A1 (en) Multimeric protein engineering
CN101413002A (en) Recombinant Kluyveromyces sp. expressing antibody or antibody analogue, and construction method and use thereof
TWI628279B (en) Recombinant yeast transformant and process for preparing immunoglobulin fc fragment employing the same
EP1619208B1 (en) Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein
KR20100021627A (en) Expression of soluble antibody fragment by truncation of ch1 domain
RU2407796C2 (en) FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION
JPH07106159B2 (en) Protein anti-cancer drug
JPWO2019161167A5 (en)
CN109265564A (en) A kind of mouse AntiCD3 McAb recombinant immunotoxin and its preparation method and application
CN108300725A (en) Soluble single-chain antibody super antigen fusion and albumen and its preparation and application
JP4892717B2 (en) Chicken chimeric antibody and use thereof
JPH02500640A (en) A method of producing a polypeptide of interest in a host organism transformed with a recombinant DNA comprising a nucleic acid sequence encoding the polypeptide and a protein with affinity for the sugar. Applications, especially in the production of vaccine compositions
JP2006500923A (en) IgE protein variants and uses thereof
TWI776048B (en) Recombinant protein for preventing swine fever virus infection and composition and cell comprising the same.
JPS60502136A (en) Expression of interlukin 2 by microorganisms
CN120210168A (en) Method for reducing immunogenicity of medical enzyme, medical enzyme, preparation method and application thereof

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner